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29 Abstract: Snakebite is a neglected tropical disease that disproportionately affects the poor. 
30 Antivenom is the only specific and effective treatment for snakebite, but its distribution is 
31 severely limited by several factors, including the prohibitive cost of some products. Papua 
32 New Guinea (PNG) is a snakebite hotspot but the high costs of Australian antivenoms 
33 (thousands of dollars per treatment) makes it unaffordable in PNG. A more economical 
34 taipan antivenom has recently been developed at the Instituto Clodomiro Picado (ICP) in 
35 Costa Rica for PNG and is currently undergoing clinical trials for the treatment of 
36 envenomations by coastal taipans (Oxyuranus scutellatus). In addition to potentially having 
37 the capacity to neutralise the effects of envenomations of non-PNG taipans, this antivenom 
38 may have the capacity to neutralise coagulotoxins in venom from closely related brown 
39 snakes (Pseudonaja spp.) also found in PNG. Consequently, we investigated the cross-
40 reactivity of taipan antivenom across the venoms of all Oxyuranus and Pseudonaja species. 
241 In addition, to ascertain differences in venom biochemistry that influence variation  in 
42 antivenom efficacy, we tested for relative cofactor dependence. We found that the new ICP 
43 taipan antivenom exhibited high selectivity for Oxyuranus venoms and only low to 
44 moderate cross-reactivity with any Pseudonaja venoms. Consistent with this genus level 
45 distinction in antivenom efficacy were fundamental differences in the venom biochemistry. 
46 Not only were the Pseudonaja venoms significantly more procoagulant, but they were also 
47 much less dependent upon the cofactors calcium and phospholipid. There was a strong 
48 correlation between antivenom efficacy, clotting time and cofactor dependence. This study 
49 sheds light on the structure-function relationships of the procoagulant toxins within these 
50 venoms and may have important clinical implications including for the design of next-
51 generation antivenoms. 
52
53 Keywords: Oxyuranus, Pseudonaja, venom, antivenom, ICP antivenom, coagulotoxic, 
54 prothrombinase complex, coagulopathy, disseminated intravascular coagulation, venom 
55 induced consumptive coagulopathy
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57 1. Introduction
58 Snakebite is a neglected tropical disease that disproportionately affects the poorest 
59 nations (Harrison et al., 2009). The prevalence of snakebite and resultant health 
60 repercussions in Papua New Guinea (PNG) renders residents of this economically 
61 disadvantaged nation at particularly high risk. Indeed, the death rate from snakebite in some 
62 parts of PNG is estimated to be an alarming 7.9 people per 100,000 inhabitants (Lalloo et 
63 al., 1995a), compared to 0.13 deaths per 100,000 people in Australia (Welton et al., 2017).
64 Snakebite in poor, rural settings in tropical regions is not only a serious public health 
65 hazard but also a data-deficient issue, as record keeping is either of poor quality or entirely 
66 absent. For example, while the Port Moresby (south eastern PNG) area has been the subject 
67 of intensive snakebite research (Lalloo et al., 1995b; Williams et al., 2007, 2005), which 
68 indicated that O. scutellatus is by far the greatest hazard regarding snakebite in that region, 
69 the incidence of P. textilis bites and resulting fatalities in Oro Province where these snakes 
70 are common (O’Shea, 1996) is still unknown and may be high. 
71 The genera Oxyuranus and Pseudonaja form a monophyletic clade, containing snakes 
72 which are very dangerous to humans because their venom has evolved to incapacitate 
73 mammalian prey rapidly by inducing stroke, likely as a consequence of selection pressures 
74 to reduce the risk of retaliation by these dangerous prey animals. This acute effect on 
75 mammals is mirrored clinically in humans: people have collapsed from Pseudonaja 
76 envenoming in just 15 minutes (not due to anaphylaxis) (Sutherland and Tibballs, 2001). 
377 The etiology of “rapid collapse” following brown snake envenoming is poorly understood, 
78 but bites from these snakes typically result in severe disruption of hemostasis (Chaisakul et 
79 al., 2013; Lalloo et al., 1995b), characterised by venom-induced consumptive coagulopathy 
80 (VICC) (Allen et al., 2012; Isbister et al., 2010b). In humans, this irreversible and life-
81 threatening condition is caused by procoagulant toxins that consume essential blood 
82 coagulation proteins and results in a net anticoagulant effect with occasional hemorrhaging 
83 (Isbister, 2009; Maduwage and Isbister, 2014; Sutherland and Tibballs, 2001). These 
84 sequelae persist until blood clotting factors have been replaced (resynthesised) by the body, 
85 and death may result from internal bleeding such as cerebral hemorrhage.
86 Oxyuranus and Pseudonaja species contain in their venoms activated forms of proteins 
87 homologous to the blood coagulation factors X (FXa) (Trabi et al., 2015) and V (FVa) (Earl 
88 et al., 2015), which together form the prothrombinase complex responsible for the 
89 aforementioned coagulopathy. These powerful procoagulant toxins share 48-54% sequence 
90 identity with human endogenous prothombinase (Bos and Camire, 2010; St. Pierre et al., 
91 2005) and have acquired several unique gain-of-function features that make them more 
92 potent than the endogenous FXa:FVa prothrombinase complex (Bos et al., 2009; Lavin and 
93 Masci, 2009). For instance, the FVa subunit of these toxins has been shown to escape 
94 hemostatic downregulation by activated protein C (Bos et al., 2009), the natural inactivator 
95 of endogenous FVa. While a procoagulant toxin derived from FXa was likely present in the 
96 venoms of the common ancestor of most Australian elapids (Fry et al., 2008), the action of 
97 the plesiotypic toxic form of FXa is rate-limited by its requirement for the endogenous 
98 cofactor FVa to cleave prothrombin (Factor II) into thrombin (Factor IIa) to trigger blood 
99 clotting. However, FVa was additionally recruited into the venom of the 
100 Oxyuranus+Pseudonaja clade (Fry et al., 2008) thereby enabling injection of the complete 
101 prothrombinase complex (FXa:FVa), without the need to bind to endogenous FVa (Kini, 
102 2005; Palta et al., 2014); this event increased the efficiency of coagulotoxic effects by 
103 eliminating this rate limiting step. 
104 Another key efficiency adaptation in the Oxyuranus+Pseudonaja clade is the reduced 
105 dependence of this FXa:FVa prothrombinase toxin complex upon the cofactors calcium and 
106 phospholipid relative to that of the endogenous FXa:FVa complex. While calcium and 
107 phospholipid are often required as cofactors by toxins to initiate their disruption of 
108 haemostasis (Kini et al., 2002; Rosing et al., 1980), the FXa:FVa prothrombinase complex 
109 in the venoms of this clade can function in their absence (Bos et al., 2009; Kini et al., 
110 2002). The recruitment of FVa into these venoms and their lessened cofactor dependence 
111 are key evolutionary innovations which likely contribute to the high coagulotoxicity of the 
112 venoms of snakes in these genera compared to other venomous species (Broad et al., 1979; 
4113 Mirtschin and Davis, 1982). Furthermore, this procoagulant complex makes up a large 
114 percentage of the total protein composition of these venoms: 10-20% of the total O. 
115 scutellatus venom (Lavin and Masci, 2009) and 20-40% of P. textilis venom (Lavin and 
116 Masci, 2009; Rao and Kini, 2002).  
117 To counter the rapid and devastating pathology in envenomed patients bitten by 
118 Oxyuranus and Pseudonaja species, early treatment with effective antivenom is required 
119 (Winkel et al., 2006).  However, in Papua New Guinea the high cost of Australian-
120 produced antivenom has historically limited its availability and accessibility. Up to 80% of 
121 health facilities have no antivenom supplies at all, and in some areas of high snakebite 
122 burden there is only enough antivenom available each year to treat 15% of snakebite 
123 patients (Williams et al., 2005). This large gap between supply and demand sometimes 
124 leads to theft or unscrupulous marketing of antivenoms specific to other regions (Warrell, 
125 2008). In addition, treatment is sometimes delayed within hospitals in an effort to avoid 
126 exhausting this precious product; this delay can have devastating effects because early 
127 administration is crucial to favourable clinical outcomes (Trevett et al., 1995).  
128 While Seqirus (formerly CSL Limited, Australia) taipan (monovalent) antivenom is 
129 available in PNG at a cost of ~US$1,270/vial, Seqirus brown snake (monovalent) 
130 antivenom is not available. The only current specific treatment for Pseudonaja 
131 envenomations is Seqirus polyvalent antivenom, but one vial can cost up to US$1,670 in 
132 PNG, which is almost 60% of the per capita GDP. The high cost of Australian-made 
133 antivenoms substantially impacts availability, but fortunately a new antivenom for taipan 
134 envenoming (Papuan taipan antivenom ICP; Instituto Clodomiro Picado, Costa Rica) 
135 which performed well in preclinical (Vargas et al., 2011) and clinical trials and is expected 
136 to cost less than 25% of the current product price may ease this crisis.
137 Antivenom is a plasma-derived product which contains antibodies produced by an 
138 immunised animal (usually a horse or sheep) that neutralise particular venom components. 
139 Homogeneity in toxin compositions and toxin structure/function sometimes means that an 
140 antivenom produced using venom from one snake species may afford paraspecific cross-
141 protection against the venoms of other, generally closely related species of snake due to 
142 extensive shared evolutionary history. For example, substantial cross-reactivity of tiger 
143 snake antivenom was recently demonstrated across multiple closely-related genera 
144 diverging 8–10 million years ago (Lister et al., 2017). Oxyuranus and Pseudonaja are sister 
145 taxa diverging <15 million years ago (Sanders et al., 2008). This close phylogenetic 
146 relatedness is echoed by similar venom composition and sequence homology in the 
147 FXa:FVa prothrombinase complex (93% similarity of the FXa subunits and 97% similarity 
148 of the FVa subunits). Thus, the new ICP taipan antivenom may also neutralise toxins in the 
5149 venoms of other Oxyuranus species, and perhaps also those of Pseudonaja venoms, albeit 
150 to variable degrees since the venoms may contain significantly different levels of FXa and 
151 FVa (Barber et al., 2012).
152 In this study, we used crude venom from adult snakes in functional tests to 1) quantify 
153 the relative procoagulant activity across all recognised species in the medically significant 
154 Oxyuranus+Pseudonaja clade, 2) use cofactor dependence tests as a probe to better 
155 understand the structure-function relationship differences in the FXa:FVa prothrombinase 
156 complex of Oxyuranus and Pseudonaja venoms, and 3) determine the relative efficacy of 
157 ICP taipan antivenom in neutralising the coagulotoxic effects of Oxyuranus and 
158 Pseudonaja venoms. We hypothesised that 1) the Pseudonaja venoms would be more 
159 coagulotoxic than Oxyuranus venoms, 2) lessened dependence upon calcium and/or 
160 phospholipid cofactors would potentiate the coagulotoxic effect of all 28 venoms in this 
161 study and 3) due to the close evolutionary relationship between the Oxyuranus and 
162 Pseudonaja genera which is reflected in very high sequence similarity between their toxins, 
163 the ICP Taipan antivenom would cross-react with Pseudonaja venoms.
164 2. Materials and Methods 
165 2.1 Venom collection and preparation
166 We studied whole venoms from nine Oxyuranus samples and 19 Pseudonaja samples 
167 (Table 1), covering all currently recognised species (three and nine, respectively) within 
168 these two genera. Our samples included several populations from most species to account 
169 for intraspecific venom variation; this can be important, as P. textilis venoms may vary in 
170 toxicity across their range (Flight et al., 2006). To account for possible individual variation 
171 in expression levels (Chippaux, 1998), we were able to represent 10 out of the 12 species in 
172 this study with at least two individuals, with the exception of one sample each from P. 
173 guttata and P. modesta, as they are less commonly maintained in captivity. 
174 Only adult venoms were used to avoid ontogenetic variation in venoms, particularly 
175 since this has been previously documented in Pseudonaja (Cipriani et al., 2017). All 
176 venoms were extracted, flash-frozen, then lyophilised, and later reconstituted in deionised 
177 water, centrifuged (5 min., 4°C 14,000 RCF), and the supernatant was diluted to a 
178 concentration of 1 mg/mL with 50% glycerol to prevent freezing at -20°C. Protein 
179 concentrations were determined in triplicate using a NanoDrop 2000 UV-Vis 
180 Spectrophotometer (Thermofisher, Sydney, NSW, Australia) at an absorbance of 280 nm.
181 Venoms were sourced from individual snakes (captive and wild-caught) from either the 
182 long-term cryogenic collection of the Venom Evolution Laboratory, Venom Supplies Pty 
183 Ltd, or Reptile Kingdom Australia. We did not consider venoms from either wild-caught or 
184 captive individuals to be a confounding variable in our study because McCleary et al. 
6185 (2016) found captivity had no effect on venom composition over time in Pseudonaja. 
186 Snakes were milked using traditional methods (membrane method) or via the pipette-tip 
187 method for low-yielding Pseudonaja species (Mirtschin et al., 2006).   
188
189 2.2 Antivenom
190 A monospecific taipan antivenom (Lot#: 5330913TALQ; Exp: 09/16) manufactured at 
191 Instituto Clodomiro Picado (ICP) was used. This antivenom is a whole IgG preparation 
192 obtained from the fractionation by caprylic acid of plasma from horses immunised with the 
193 venom of O. scutellatus from PNG (Vargas et al., 2011). 
194
195 2.3 Plasma collection and preparation
196 Human plasma was collected from healthy human donors, with sodium citrate used as 
197 an anticoagulant, and donated by Australian Red Cross (research approval #16-04QLD-10; 
198 44 Musk Street, Kelvin Grove, Queensland 4059). Two batches of pooled plasma (Label 
199 #3991594 (O-) and label #3985833 (B+), citrate 3.2%) were further pooled and aliquoted, 
200 then flash-frozen in liquid nitrogen and immediately stored at -80°C until required. When 
201 required, plasma was rapidly thawed at 37°C in a Thermo Haake ARCTIC immersion bath 
202 circulator SC150-A40 and immediately used for experimentation. Plasma aliquots were 
203 replaced every hour at maximum to maintain freshness. 
204
205 2.4 Procoagulation tests
206 Clotting times of human plasma by venom were automatically measured using a STA-
207 R Max® analyser (Stago, Asnières sur Seine, France) in an 8-point series of decreasing 
208 venom concentrations (μg/mL: 20, 10, 4, 1.6, 0.66, 0.25, 0.125, 0.05). Once the venom 
209 sample was loaded into the machine, pipetting (and diluting, when appropriate) into small 
210 cuvettes occurred automatically, according to our pre-programmed experimental 
211 methodologies. Venom and plasma were replaced every 15–30 min to minimise enzymatic 
212 degradation. All tests were performed in triplicate.
213 For each test performed, 50 µL phospholipid (cephalin prepared from rabbit cerebral 
214 tissue adapted from STA C.K Prest standard kit, Stago Catalog # 00597, solubilised in 5 
215 mL of Owren Koller (OK) Buffer [Stago Cat# 00360]), 25 µL OK buffer and 50 µL CaCl2 
216 (0.025 M, Stago Catalog # 00367) were added to 50 µL venom (0.1 mg/mL) in the cuvette, 
217 as they are known cofactors usually required for activity (Nakagaki et al., 1992; St. Pierre 
218 et al., 2005). For other dilution points, the 50 µL of venom (0.1 mg/mL) was automatically 
219 diluted by the machine to complete the 8-point dilution series of decreasing venom 
220 concentrations (20–0.05 μg/mL). Once all reagents were added, the cuvette was shaken 
7221 briefly by the machine to mix the components and then incubated at 37C for 120 seconds 
222 (to allow for antivenom to bind to the venom in antivenom tests) before plasma (75 µL) 
223 was added immediately prior to the clotting-time, which was measured in seconds for a 
224 maximum of 999 seconds. Reagents were kept at 15–19C in the machine.
225 Positive controls were performed daily to test the quality of the plasma and reagents. 
226 For these tests, Kaolin (a coagulation activator) (Stago C.K Prest standard kit, Stago 
227 Catalog #00597) replaced venom in the cuvette. The average clotting time for these 
228 controls was 56.8 ± 2.2 s (n=35), as determined by daily tests performed over an 
229 approximately one-month period. 
230 Negative controls were also performed daily, where 1:1 water/glycerol replaced venom 
231 in the tests. The average clotting time for these controls was 496.9 ± 124.4 s (n=36). 
232 Venoms were considered non-coagulant if the highest concentration of venom (20 μg/mL) 
233 produced clotting times within the standard error of the negative control (i.e. over 372.5s). 
234 For these venoms, dose-response curves were not performed. 
235
236 2.5 Cofactor dependence tests
237 To determine the level of cofactor dependence of the venoms, the aforementioned 
238 coagulation tests were conducted again at the highest venom concentration (20 μg/mL)—
239 also in triplicate—with either calcium or phospholipid being replaced with 50 µL OK 
240 Buffer. In addition, to determine whether cofactor dependence trends observed at 20 μg/mL 
241 of venom persisted at a lower concentration of venom, we repeated these tests at 5 μg/mL. 
242 Calcium and phospholipid dependence values were calculated for each venom using the 
243 results from the 20 μg/mL tests. These dependence values were calculated by dividing the 
244 clotting times for each venom without the cofactor by clotting times with the cofactor 
245 present in the assay.
246
247 2.6 Antivenom efficacy tests
248 The efficacy of ICP antivenom was tested against all venoms in this study by 
249 substituting in the aforementioned venom dose-response curves 25 µL of a mixture with 
250 antivenom diluted 1:10 in OK Buffer (2.5uL antivenom in 25uL total), which would have a 
251 final dilution of 1/100 (2.5uL antivenom in 250uL total volume). This 1/100 concentration 
252 of antivenom was chosen based on the neutralising effect that 2.5uL of antivenom (out of a 
253 total 250uL volume) was observed against a 20ug/mL concentration of the immunising 
254 venom (O. scutellatus (PNG locality)). To calculate antivenom efficacy, the AUC values 
255 for the venom+antivenom dose-response curves were divided by the venom-only dose-
256 response curve AUC values, then subtracted by 1 (so that no shift in AUC values (a value 
8257 of 1 divided by 1) would have a value of 0 instead of 1). Negative controls using a 10% 
258 antivenom solution instead of venom were run to determine whether antivenom had any 
259 effect on the plasma. The average clotting time for these controls was 650.6 ± 115.5 s 
260 (n=21), which was significantly different than the venom negative control tests stated above 
261 (496.9 ± 124.4 s (n=36)). 
262 2.7 Factor Xa activity test
263 We tested the relative factor Xa activity of all venoms using a Thermo Scientific™ 
264 Fluoroskan Ascent™ Microplate Fluorometer by adding the following (per venom in 
265 triplicate) to a 384-well plate (black, Lot#1171125, nunc™ Thermo Scientific, Rochester, 
266 NY, USA) kept at 37°C: 10 µL each of CaCl2 (0.025 M, Stago Catalogue # 00367) and 
267 phospholipid (as described in section 2.4), and 10 μl venom (1 ng/μL). Immediately 
268 thereafter, 60 μL of quenched fluorescent substrate (20 µL/5 mL OK buffer) was 
269 automatically dispensed into each well (total volume of 100 µL in each well) using the 
270 following substrate: ES002 (Mca-R-P-K-P-V-E-Nval-W-R-K(Dnp)-NH2) (Lot#: DKC10, 
271 www.rndsystems.com). 
272 The plate was shaken automatically for three seconds before each reading and the 
273 fluorescence (a measure of the venom’s action on the substrate) was recorded for 300 
274 measurement cycles (400 minutes or until activity ceased) following the instructions of the 
275 substrate manufacturer (filter pairs: 320/405 nm, excitation/emission) using the software 
276 Thermo Fluoroskan Ascent™ 2.6. 
277 Human Factor Xa enzyme (0.01 µg/µL) (7.5 mg/mL HCXA -OO60 - R & D systems) 
278 was used as positive control to ensure functionality of the substrate. The measurement of 
279 blank wells with substrate and OK buffer only was subtracted from all other measurements 
280 to eliminate any background activity (ie. fluorescence by the substrate and/or OK buffer 
281 alone). Raw data were organised using Excel 2016 and then analysed using Prism 7.0. All 
282 data were normalised for presentation purposes. 
283
284 2.8 Statistical analyses
285 All dose-response curves, as well as cofactor dependence tests, were analysed using 
286 Prism 7.0 software (GraphPad Software Inc, La Jolla, CA, USA) and Rstudio. ANOVAs 
287 and t-tests were conducted using GraphPad Prism 7.0a. ANOVAs were conducted to test 
288 whether multiple groups (e.g. P. textilis localities) were significantly different. T-tests were 
289 used to assess whether two groups being compared (e.g. Oxyuranus vs. Pseudonaja) were 
290 significantly different. A D’Agostino-Pearson normality test was conducted to determine 
291 normality of the data prior to analyses. When the data were not normally distributed, a 
292 Kruskal-Wallis test or Mann-Whitney U-test was used instead of ANOVAs or t-tests, 
9293 respectively. Area under the curve (AUC) values for the venom and antivenom 
294 concentration curves were calculated using Prism 7.0 software. For all statistical tests, p-
295 values ≤  0.05 were considered statistically significant. The results are expressed as the 
296 mean ± SD.
297 The phylogenetic tree used for visual representation of the data was based on 
298 previously published trees (Sanders et al., 2008; Skinner et al., 2005) and re-created 
299 manually using Mesquite software (version 3.2). This tree was then used for all 
300 comparative analyses in Rstudio using the APE package for basic data manipulation 
301 (Paradis et al., 2004). In order to investigate the evolutionary relationships of traits, 
302 ancestral states were estimated over the tree using maximum likelihood in the contMap 
303 function of the R package phytools (Revell, 2012). We then fit PGLS (phylogenetic 
304 generalised least squares) models (Symonds and Blomberg, 2014) in caper (Orme et al., 
305 2015) to test whether dependence on either calcium or phospholipid cofactors influenced 
306 clotting time, and also whether phospholipid dependence is related to calcium dependence. 
307 Coding for the R-analyses is in Supplementary File 1.
308
309 3. Results
310 3.1 Procoagulant venom activity
311 We conducted a total of 150 dose-dependent coagulation curves (25 in triplicate each 
312 for coagulation curves and antivenom curves) across all currently recognised Pseudonaja 
313 species (9) and Oxyuranus species (3). Whether compared by clotting time at maximal 
314 concentration (20 μg/mL) or full clotting curve via Area Under the Curve (AUC), the same 
315 phylogenetic patterns were observed (PGLS df = 1, t = 11.4880, p = 1.1 x 10-11) in that 
316 Pseudonaja venoms were appreciably more toxic than Oxyuranus venoms (Figure 1). 
317 Consistent with data reported by Jackson et al. (2016), we found only very weak 
318 procoagulant properties in P. modesta venoms (337.0 ± 4.4 s clotting time at the 20 μg/mL 
319 concentration relative to the spontaneous clotting time of plasma without venom (496.9 ± 
320 20.74 s SD, n = 36)). In agreement with Barber et al. (2014), we also found a similar lack of 
321 discernable procoagulant effects for O. temporalis venom (>421.0 s with 20 μg/mL venom 
322 vs 496.9 ± 20.74 s SD without venom) (Table 1). All other venoms displayed potent 
323 procoagulant effects, with a non-parametric Mann-Whitney U-test revealing that 
324 Pseudonaja venoms exhibited significantly more potent coagulotoxic effects than 
325 Oxyuranus venoms (Mann-Whitney U-test = 4, N=25, P < 0.0001). 
10
326 In contrast to data reported by Flight et al. (2006) and Skejic and Hodgson (2013), we 
327 found no significant difference (Kruskal-Wallis test: p = 0.52) among the procoagulant 
328 activities of P. textilis venoms samples from four localities up to 1,785km apart.
329
330 3.2 Cofactor dependent clotting
331 Our PGLS (phylogenetic generalised least squares) analyses revealed that calcium 
332 dependence and phospholipid dependence both predict clotting time, such that venoms with 
333 greater cofactor independence produced faster clotting times (Fig. 2; calcium: PGLS: df = 
334 1, t = 4.3042, p = 2.11 x 10-04; phospholipid: df =1, t = 1.9902, p = 0.05718, Fig. 3). 
335 Calcium dependence was found to be an extremely strong predictor of phospholipid 
336 dependence (PGLS: df = 1, t = 7.7003, p = 3.592x 10-08; Fig. 4), such that venoms either 
337 relied heavily on both cofactors or neither. 
338 Surprisingly, not all venoms were potentiated with the addition of phospholipid. In 
339 fact, the opposite effect was observed for some Pseudonaja venoms, which showed faster 
340 clotting times in the absence of phospholipid (but were still faster than Oxyuranus venoms 
341 even in the presence of phospholipid) (Table 1, Fig. 3). The exception to this within the 
342 Pseudonaja was the monophyletic clade of P. affinis, P. aspidorhyncha, and P. inframacula 
343 that showed phospholipid dependence. 
344 Cofactor dependence tests performed at a lower concentration (5 μg/mL) revealed that 
345 all venoms shifted towards more cofactor dependence at the lower venom concentration 
346 (Supplementary Figures S1 and S2). Only slight variations were observed in the most 
347 dependent venoms, whereas the least dependent venoms remained so at both venom 
348 concentrations. 
349
350 3.3 Antivenom efficacy
351 The taxonomical selectivity of ICP Taipan antivenom for Oxyuranus venoms was 
352 consistently higher compared to Pseudonaja venoms (PGLS: df = 1, t = 4.9364, p = 3.974 x 
353 10-5; Fig. 5). Specifically, the antivenom neutralised all Oxyuranus venom samples but 
354 performed comparably poorer against the Pseudonaja species. Examination of the well-
355 neutralised Oxyuranus clade revealed no correlation between antivenom efficacy and 
356 clotting time (PGLS: df = 1, t = -0.0670, p = 0.9492). Thus the poor neutralisation of 
357 Pseudonaja venoms was likely due to surface biochemistry rather than speed of action.
358
359 3.4 Factor Xa substrate activity
360 P. guttata venom had the highest activity upon the synthetic FXa substrate, with P. 
361 textilis venoms having slightly lower activity, and the two procoagulant Oxyuranus species 
11
362 showed the lowest activity levels. For all venoms, higher substrate activity was typically 
363 related to faster clotting times, and this was significant (PGLS: df = 1, t = -1.9682 (a 
364 negative value due to the inverse relationship between clotting time and substrate cleavage), 
365 p = 0.0598; Fig. 6). The greater variability for substrate cleavage versus clotting time 
366 reflected the fact that the substrate was an artificial environment.
367
368 4. Discussion
369 We set out to determine the relative procoagulant activity (Fig. 1; Table 1), cofactor 
370 dependence (Fig. 2-4; Table 1), ICP Taipan antivenom efficacy (Fig. 5; Table 1), and FXa 
371 substrate specificity (Fig. 6) across all species within the medically significant genera 
372 Oxyuranus and Pseudonaja. Within species displaying coagulotoxicity (all other than O. 
373 temporalis or P. modesta that showed no such activity), all species of Pseudonaja were 
374 significantly more procoagulant than Oxyuranus spp., with P. textilis populations having 
375 the most procoagulant venoms. Cofactor dependence varied according to a significant 
376 phylogenetic signal and was significantly positively correlated with clotting time, meaning 
377 that the relative dependence of venoms on cofactors corresponded with clotting time 
378 patterns. Cofactor dependence patterns across the venoms still persisted at a lower venom 
379 concentration (5 μg/mL, compared to 20 μg/mL). The ICP Taipan antivenom (made using 
380 only Papua New Guinea O. scutellatus venom in the immunising mixture, in ‘naïve’ horses 
381 with no prior exposure to other venom antigen mixtures) exhibited highly significant 
382 selectivity for Oxyuranus venoms and displayed little or no cross-reactivity with 
383 Pseudonaja venoms. Within the well-neutralised Oxyuranus clade, clotting times (ie. 
384 potency of venoms) was not a significant predictor of antivenom efficacy (t = -0.0670, p = 
385 0.9492). Factor Xa activity on artificial substrate moderately corresponded with relative 
386 clotting times on whole plasma.
387
388 4.1 Procoagulant venom activity
389 The rank order of procoagulant potency of Oxyuranus venoms in this study was: O. 
390 scutellatus were on average slightly faster than O. microlepidotus, while O. temporalis was 
391 non-coagulotoxic. For Pseudonaja venoms, the order was: P. textilis > P. ingrami > P. 
392 guttata > P. mengdeni > P. nuchalis > P. affinis > P. aspidorhyncha > P. inframacula, 
393 while P. modesta was non-coagulotoxic (See Table 1). 
394 Despite the FXa:FVa complex being characteristic of Oxyuranus and Pseudonaja 
395 venoms (relative to other coagulotoxic Australian elapids which contain only FXa in their 
396 venom), the fact that all venoms exhibited varying clotting times within each genus 
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397 suggests possible dissimilarities in the functional residues across species. While FVa was 
398 recruited into the common Oxyuranus/Pseudonaja ancestor (Fry et al., 2008), venom speed 
399 of action was substantially faster within Pseudonaja (Fig. 1). This parallels the reduction in 
400 cofactor dependence in the same phylogenetic positions (see Fig. 2 and 3 and section 3.2).
401 While Pseudonaja venoms in this study were markedly more procoagulant than 
402 Oxyuranus venoms (Fig. 1; Table 1), it is important to note that Barber et al. (2012) found 
403 Oxyuranus venoms were more neurotoxic when tested in the chick biventer cervicis nerve-
404 muscle preparations. This is consistent with our knowledge of clinical syndromes of 
405 envenoming by Oxyuranus consisting of neurotoxicity and coagulopathy, whereas 
406 envenoming by Pseudonaja is coagulopathic (Flight et al., 2006; Sutherland and Tibballs, 
407 2001). 
408 Interestingly, although some studies found a significant difference in procoagulant 
409 activity from the venoms of northern (QLD) and southern (SA) localities of P. textilis 
410 (Flight et al., 2006; Skejić and Hodgson, 2013), we found no evidence of variation in 
411 procoagulant activity among four very disparate localities spanning 1,785Km. While more 
412 venoms and data are required for a robust test of geographical variation in procoagulant 
413 activity of P. textilis venoms, our results suggest that there may not be a functional 
414 difference in the procoagulant enzyme levels across the species’ distribution. Instead, the 
415 discrepancy may be due to the ontogenetic changes in Pseudonaja venoms from neurotoxic 
416 to coagulotoxic from juveniles to adults (Cipriani et al., 2017; Jackson et al., 2016). 
417 Previous geographical studies may have used venom from subadult snakes—no snake sizes 
418 were reported—for the South Australian populations which would be consistent with the 
419 lower coagulotoxicity. In contrast, this study used venom only from adult snakes in order to 
420 make meaningful comparisons across ranges and between species. 
421
422 4.2 Variability in cofactor dependence
423 In vivo, plasma contains platelets (among other additional blood components), which 
424 possess calcium and phospholipids that assist in the biochemical reactions of the blood 
425 coagulation cascade. Because citrated plasma (calcium removed) used in in vitro testing is 
426 separated from and void of platelets, it is particularly important to reintroduce the cofactors 
427 calcium and phospholipid in order to best model and test these systems. Indeed, our 
428 cofactor dependence results indicate that the omission of these cofactors from venom 
429 assays will result in skewed data. While some previous venom studies included calcium and 
430 phospholipid cofactors in their clotting assays (Bos et al., 2016; Chester and Crawford, 
431 1982; Owen and Jackson, 1973; Sousa et al., 2018), others failed to include either 
432 phospholipid (Isbister et al., 2010b; Nielsen et al., 2017; O’Leary and Isbister, 2010; Still et 
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433 al., 2017; Vargas et al., 2011), or both calcium and phospholipid (Ainsworth et al., 2018; 
434 Williams et al., 1994). 
435 We found that relative cofactor dependence was proportional to clotting time, with the 
436 fastest clotting venoms also being the least dependent (Fig. 2-3; Table 1). The elimination 
437 of biochemical steps in the coagulation cascade could be advantageous by increasing 
438 catalytic activity, thereby potentiating progress towards a fibrin clot. This may explain why 
439 more calcium- and phospholipid-independent venoms are more potently coagulotoxic. We 
440 also found that calcium dependence and phospholipid dependence positively co-varied 
441 (Fig. 4). This relationship was expected because calcium mediates the interaction between 
442 blood coagulation proteins and the negatively charged phospholipid surface (Bos et al., 
443 2016), so the two cofactors are mechanistically linked. There were, however, significant 
444 differences between the two genera regarding the influence of calcium and phospholipid. 
445 Further, our investigation demonstrated that cofactor dependence is far more variable in 
446 Pseudonaja than previous work suggests (Chester and Crawford, 1982; Rosing and Tans, 
447 1992). 
448 Calcium and phospholipid dependence patterns across the venoms remained largely the 
449 same between both venom concentrations (5 μg/mL vs. 20 μg/mL) (Figure S1 and S2), with 
450 all venoms shifting toward more cofactor dependence at the lower venom concentration. 
451 Only slight variations in the most dependent venoms were observed, and the least 
452 dependent venoms remained so at both venom concentrations. Pseudonaja venoms that 
453 accelerated clotting time in the absence of phospholipid did not do so at 5 μg/mL, 
454 indicating that, when the venom is more concentrated (e.g. in prey items), it is able to 
455 overwhelm its target without dependence on cofactors; whereas at a lower venom 
456 concentration, greater cofactor dependence becomes more evident. Given that cofactor 
457 effects on venom are even more pronounced at lower venom concentrations, it is 
458 fundamentally important to include cofactors in in vitro venom studies that involve 
459 evolutionary and pathophysiological interpretations.
460 While the FXa:FVa prothrombinase complex in Oxyuranus and Pseudonaja venoms 
461 can function in the absence of calcium and phospholipid (Bos et al., 2009; Kini et al., 
462 2002), all venoms in these genera functioned faster in the presence of calcium (Fig. 2; 
463 Table 1). In agreement with Vargas et al. (2011), our five O. scutellatus venoms showed 
464 higher in vitro coagulant activity in the presence of calcium. In contrast, the Pseudonaja 
465 venoms were in general much less dependent (up to 15-times less dependent relative to 
466 Oxyuranus), with some approaching neutral level of dependence in that the reactions were 
467 only 0.25-times faster with calcium than without. 
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468 Counterintuitively, in Pseudonaja species we found evidence for accelerated venom-
469 induced clotting in the absence of phospholipid (negative phospholipid-dependence values) 
470 at 20 μg/mL relative to the clotting times displayed in the presence of phospholipid 
471 (although these venoms were still faster than Oxyuranus even in the presence of 
472 phospholipid) (Fig. 3). The weaponised version of the prothrombinase complex in P. 
473 textilis has been shown to have 116 mutations, several of which lie within the likely 
474 prothrombin binding site and thus may result in improved activity in the absence of 
475 membranes (Lechtenberg et al., 2013), such as a phospholipid membrane surface.
476 The Pseudonaja condition where certain venoms exhibit accelerated action in the 
477 absence of phospholipid poses an interesting evolutionary question, as phospholipid (and 
478 calcium) is present in the plasma of all prey items (and humans). However, since the 
479 membranes of activated platelets and activated/apoptotic endothelial cells are the 
480 physiological source of phospholipids, and since the venom coagulotoxins probably 
481 circulate in the bloodstream without causing vascular damage, it is reasonable to presume 
482 there are naturally low phospholipid concentrations (estimated 3%) in the bloodstream 
483 (Bevers and Williamson, 2016). While some venom factors may be shown to activate 
484 platelets and produce phospholipid, the decreased reliance upon such secondary 
485 biochemical steps would facilitate faster clotting times. It is important to note that these 
486 Pseudonaja venoms were the fastest, regardless of the relative presence of phospholipid. 
487 Their acceleration in the absence of phospholipid (despite acting the fastest in the presence 
488 of phospholipid) indicates a remarkable level of functional flexibility and suggests that 
489 these enzymes may utilise alternative biochemical pathways depending on relative 
490 abundance of phospholipid.
491 Our demonstration of accelerated venom effects in low levels of phospholipid is 
492 consistent with the rapid acceleration of venom effects in Pseudonaja envenomations, in 
493 which non-anaphylactic sudden collapse occurs as the venom spreads through the blood 
494 stream (Sutherland and Tibballs, 2001). The more rapid onset of these effects in 
495 Pseudonaja envenomations than in Oxyuranus envenomations may reflect the fact that 
496 factor V in P. textilis (and possibly other Pseudonaja venoms) can function not only via 
497 membrane binding (like endogenous factors and Oxyuranus venoms) (Bos et al., 2009; 
498 Gilbert et al., 2012) but also via alternate pathways that do not require membrane binding. 
499 In prey items with much smaller blood volumes than in humans, the formation of stroke-
500 inducing blood clots by low-phospholipid-dependent coagulotoxins would accelerate after 
501 localised depletion of phospholipid, yielding a selective advantage for this venom trait. 
502 Moreover, determining the mechanism of this accelerated venom action in the absence of 
503 phospholipid has immediate implications for understanding the pathology of produced in 
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504 sudden coagulopathy-induced collapse and death in humans. Since circulating levels of 
505 phospholipid are usually low in the absence of systemic platelet activation, the ability to 
506 work in a low phospholipid environment would be evolutionarily advantageous. Similarly, 
507 eliminating one more step in the biochemical coagulation cascade would speed up the 
508 reaction and subsequent venom effects. 
509
510 4.3 Antivenom efficacy
511 Antivenom is the most effective and only specific treatment for snakebite (Maduwage 
512 and Isbister, 2014; Winkel et al., 2006) and thus critical for minimising morbidity and 
513 mortality in victims, but it can be expensive leading to poor availability across many high-
514 risk regions (Harrison et al., 2009). The snakebite mortality rate in Papua New Guinea is 
515 about 100-fold higher than in Australia, with O. scutellatus being the leading reported 
516 cause (Lalloo et al., 1995a). The ICP Taipan antivenom used in this study is a newly 
517 developed product which has financial advantages over the CSL taipan antivenom and may 
518 help to improve antivenom accessibility when it goes into production (Herrera et al., 2014). 
519 It has been suggested that CSL antivenom may be less effective in neutralising O. 
520 scutellatus venom (from PNG) than venom from the Australian nominal subspecies 
521 (Vargas et al., 2011). Likewise, stronger immunorecognition of O. scutellatus venom from 
522 Australia was recognised for CSL Taipan antivenom compared to ICP Taipan antivenom 
523 (Herrera et al., 2014). In contrast, we found that the ICP Taipan antivenom performed 
524 equally well against Australian O. scutellatus and Saibai Island O. scutellatus (Figure 5; 
525 Table 1). This cross-reactivity of taipan antivenom against both Australian and PNG O. 
526 scutellatus populations is consistent with previous studies (Crachi et al., 1999; Herrera et 
527 al., 2014; Vargas et al., 2011), which is unsurprising given the minimal genetic divergence 
528 between these populations (Doughty et al., 2007; Wüster et al., 2005). Similarly, the 
529 neutralisation of O. microlepidotus is consistent with its close genetic relationship to O. 
530 scutellatus (Wüster et al., 2005). 
531 Our demonstration of the broad efficacy of ICP Taipan antivenom across all 
532 coagulotoxic members suggests that the ICP antivenom would be appropriate for treating 
533 coagulotoxic envenomations by any Oxyuranus species. This of course should be clinically 
534 validated, but the in vitro results in this study are extremely promising and may be of use to 
535 zoological collections and private exotic animal collections across the world which house 
536 these iconic snakes and require affordable, effective antivenom.
537 Despite a high similarity in toxin sequences between Oxyuranus and Pseudonaja 
538 venoms (93% for FXa subunits and 97% for FVa subunits), the Pseudonaja venoms were 
539 comparatively less neutralised by the ICP Taipan antivenom. These results are consistent 
16
540 with previous studies showing poor cross-reactivity of antibodies against taipan venoms 
541 used against the venoms of brown snakes (Isbister et al., 2010a) and agree with the relative 
542 amounts of prothrombinase complex in these venoms (discussed further below) (Lavin and 
543 Masci, 2009; Rao and Kini, 2002). The most neutralised Pseudonaja species (P. 
544 aspidorhyncha) was still neutralised less than that of the least neutralised Oxyuranus 
545 species (O. microlepidotus from Boulia, QLD). Clearly, the small difference in toxin 
546 structure due to independent modification of the surface chemistry confers important 
547 structure-function immunological relationships of these venoms and likely has major 
548 implications for the clinical options in managing Pseudonaja bites (particularly P. textilis, 
549 as this species is also found in PNG). 
550 One explanation for the difference in neutralisation capacity by antivenom between 
551 these venoms would be varying venom potency, whereby a more potent procoagulant 
552 venom would be less well neutralised than a less potent procoagulant venom simply 
553 because of stoichiometric differences, in that venoms with lower relative levels of 
554 procoagulant toxins would be better neutralised by the same antivenom level than venoms 
555 with higher relative toxin levels. However, our examination of the well-neutralised 
556 Oxyuranus clade revealed no correlation between antivenom efficacy and clotting time 
557 (PGLS: df = 1, t = -0.0670, p = 0.9492). 
558 Hererra et al. (2012) found the coagulotoxicity of the PNG O. scutellatus to be greater 
559 than the Australian O. scutellatus population (and the latter was thus better neutralised by 
560 ICP antivenom in that study), but with a larger dataset there was no direct correlation 
561 between clotting time and antivenom efficacy. In addition to the larger Oxyuranus dataset 
562 in this study, Hererra et al. (2012) and others (Vargas et al., 2011) used a manual 
563 observation method (MCD: Minimal Coagulant Dose (Theakston and Reid, 1983)) to 
564 determine clotting time ‘by eye’ which resulted in large error bars, whereas this study used 
565 a robot-operated machine to measure clotting times, which resulted in remarkably small 
566 error bars (smaller than the line symbols in most cases). In addition, the MCD tests assume 
567 a linearity between data points when estimating the 60 second clotting dose. However, the 
568 clotting time relative to venom concentration varies in a curved rather than linear manner. 
569 Thus, our newly developed protocol affords a more accurate determination of the dose and 
570 the response and has been successfully used by us for other venoms (Debono et al., 2017; 
571 Lister et al., 2017; Oulion et al., 2018; Rogalski et al., 2017).
572 The lower cost of the ICP Taipan antivenom (less than 25% of that of the Seqirus 
573 Taipan antivenom) renders it very appealing and should substantially improve the 
574 availability of safe, clinically effective antivenom for treating taipan envenoming in PNG. 
575 While it would be advantageous to use taipan antivenom to treat envenomation by 
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576 Pseudonaja, particularly because no monovalent antivenom for Pseudonaja species is 
577 stocked in PNG, our results indicate that taipan antivenom is not likely to effectively 
578 neutralise the coagulotoxins that cause the primary pathophysiology in Pseudonaja 
579 envenomations. While strongly positive results such as those obtained here for the 
580 neutralisation of Oxyuranus venoms do not necessarily translate directly to the clinical 
581 setting, the corresponding lack of efficacy against Pseudonaja venoms suggests that there 
582 would also be lack of clinical efficacy, even at very high antivenom doses. 
583
584 4.4 Factor Xa substrate activity
585 We observed a significant correlation between clotting times and FXa activity (Fig. 6). 
586 The differences in the order of potency between these two parameters may be explained by 
587 the experimental set-up, as the clotting assays were conducted on whole plasma, while 
588 Factor Xa activity was assessed in an artificial construct acting as a proxy for the clotting 
589 system. The substrate tests did not use native proteins—the substrates are artificial—and 
590 also did not incorporate the various thrombin-mediated feedback loops that characterise 
591 endogenous fibrin clot formation; consequently, the results must be interpreted with 
592 caution, as they are far from reflecting the biological reality. This illustrates the importance 
593 of bioactivity tests using either plasma or at least native proteins such as purpose-built 
594 clotting reactions.
595
596 4.5 Study limitations
597 There are several potential limitations to this study. Firstly, given this study 
598 investigated only procoagulant effects, the antivenom efficacy seen here cannot be 
599 extended to venom effects such as neurotoxicity and myotoxicity that were not assessed. 
600 Therefore, considerations regarding the broader clinical usefulness of the ICP antivenom 
601 for all coagulotoxic Oxyuranus envenomations must consider this caveat. Secondly, while 
602 we included a diverse range of venoms, covering the entire clade, the number of individual 
603 replicates per locality was limited due to the danger, difficulty, and expense in acquiring 
604 such an extensive venom collection. In an attempt to overcome this limitation, multiple 
605 individuals per species were included where possible to account for intraspecific venom 
606 variation (Chippaux et al., 1991). Table 1 shows that there ere no substantial differences 
607 between individuals within a species. Overall, despite this sampling limitation, this work is 
608 the most diverse and comprehensive study ever undertaken for either genus.
609 A minor limitation of this study is that, while we rigorously investigated the relative 
610 dependence of snake venoms on calcium and phospholipid at two different venom 
611 concentrations, and while the plasma used in our assays was depleted of both cofactors, 
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612 there may have been trace amounts of either in the plasma, thus potentially slightly skewing 
613 the results. Future work investigating cofactor dependence of venoms should be undertaken 
614 in a plasma-free assay that utilises purified prothrombin and fibrinogen instead of plasma.
615 Lastly, being in vitro, our tests do not simulate the complex pathophysiology that 
616 occurs when snake venoms interact with multiple systems in the human body and thus 
617 could under- or over-estimate precise antivenom efficacy. However, relative antivenom 
618 efficacy across species reported here is still likely to be clinically informative. In particular, 
619 if an antivenom does not perform well in such ideal conditions as our functional assays, it is 
620 unlikely that it will perform well in a complex circulatory system with a much greater 
621 plasma-to-antivenom ratio. Thus, it is reasonable to expect that the ICP antivenom would 
622 perform poorly against Pseudonaja envenomations in a clinical setting but may offer a 
623 genus-wide option for Oxyuranus envenomations, at least in the context of coagulopathy.
624
625 5. Conclusion
626 Multiple conclusions can be made from this large dataset. This study found that 
627 cofactor dependence is far more variable (particularly in Pseudonaja) than previously 
628 considered, with some venoms accelerating in the absence of phospholipid (ie. exhibiting 
629 negative phospholipid-dependence values) at high venom concentrations, which would be 
630 expected in prey items. While the precise mechanisms and evolutionary origins of this 
631 variation remain enigmatic, and elucidating them is beyond the scope of this study, the 
632 authenticity of this result is supported by the phylogenetic signal whereby all three species 
633 within a single clade of Pseudonaja did not exhibit this effect and instead exhibited the 
634 secondary reversal to the ancestral state of greater phospholipid-dependence. 
635 Furthermore, our results indicate that, while ICP Taipan antivenom was developed 
636 using O. scutellatus venoms from PNG, it effectively neutralises the coagulotoxins of all 
637 Australian Oxyuranus venoms. As such, this antivenom may be suitable for treating 
638 envenomation by Oxyuranus in Australia or in zoological or private collections overseas, 
639 with an important caveat that neurotoxicity and myotoxicity were not tested here and also 
640 that clinical trials are ideal first for confirmation.
641 Our results suggest that this new ICP Taipan antivenom (and probably the CSL Taipan 
642 antivenom as well) is unlikely to be suitable for treating Pseudonaja envenomations 
643 without requiring very large antivenom doses to achieve even moderate neutralisation of 
644 the best neutralised species. Thus, P. textilis bites in PNG, which are of unknown 
645 frequency, remain without a readily available and affordable treatment. However, the 
646 intriguing parallels between cofactor dependence and antivenom efficacy demonstrated by 
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647 the Pseudonaja clade of P. affinis, P. aspidorhyncha and P. inframacula point the way for 
648 next-generation antivenom research efforts involving rational design of epitope targeting. 
649 Future work should ensure the inclusion of cofactors calcium and phospholipid in 
650 bioactivity tests of venoms to avoid under– or over–estimating venom potency levels. In 
651 addition, the strength of the resulting clots formed by Oxyuranus and Pseudonaja venoms 
652 should be assessed by thromboelastography to determine if weak or strong clots are formed. 
653 These future studies will provide a better understanding of the selection pressures operating 
654 upon these venoms as well as the clinical effects by these extremely medically important 
655 snakes.
656 The results of this study are of clinical importance for understanding the relative 
657 coagulotoxicity across all species of Oxyuranus and Pseudonaja. The  also provide a 
658 platform for future research investigate the efficacy of different antivenoms and unveil the 
659 structure-function relationships of the potent FXa:FVa prothrombinase complex across 
660 these venoms.
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930 Figure 1. Ancestral state reconstruction of clotting times (sec) (left side) compared area 
931 under the clotting curves (AUC) (right side) of venoms, where warmer colours represent 
932 faster clotting times. Maximal clotting time was shown to be a strong predictor of clotting 
933 AUC (PGLS df = 1, t = 11.4880, p = 1.1 x 10-11). Bars indicate 95% confidence intervals 
934 for the estimate at each node. Note: due to the high dynamicity of venom evolution, the 
935 ranges quickly become broad as one moves down the tree. Lineages in grey are non-
936 coagulotoxic. ND = Not detectable due to non-procoagulant venom. 
937
938 Figure 2. Ancestral state reconstruction of clotting times (sec) at 20 μg/mL maximal 
939 concentration tested (left side) compared to calcium dependence (the shift in clotting time 
940 between conditions in the presence vs. absence of calcium) (right side) of venoms, where 
941 warmer colours represent faster clotting times or higher dependence on calcium. Calcium 
942 dependence showed very strong correlation with clotting time (PGLS df = 1, t = 4.3042, p 
943 = 2.11 x 10-04) and was a good predictor of the latter parameter. Bars indicate 95% 
944 confidence intervals for the estimate at each node. Note: due to the high dynamicity of 
945 venom evolution, the ranges quickly become broad as one moves down the tree. Lineages 
946 in grey are non-coagulotoxic. ND = Not detectable due to non-procoagulant venom. A 
947 value of zero would indicate no change with or without calcium.
948
949 Figure 3. Ancestral state reconstruction of clotting times (sec) at 20 μg/mL maximal 
950 concentration tested (left side) compared to phospholipid dependence (right side) (the shift 
951 in clotting time between conditions in the presence vs. absence of phospholipid) of venoms, 
952 where warmer colours represent faster clotting times or higher dependence on 
953 phospholipid. Phospholipid dependence showed a significant correlation with clotting time  
954 (PGLS df = 1, t = 1.9902, p = 0.05718) and was a good predictor of the latter parameter. 
955 Error bars at the nodes indicate 95% confidence intervals for the estimate at each node. 
956 Note: due to the high dynamicity of venom evolution, the ranges quickly become broad as 
957 one moves down the tree. Lineages in grey are non-coagulotoxic. ND = Not detectable due 
958 to non-procoagulant venom. Negative values indicate that clotting times were quicker in the 
959 absence of phospholipid. A value of zero would indicate no change with or without 
960 phospholipid.
961
962 Figure 4. Ancestral state reconstruction of calcium dependence (left side) (the shift in 
963 clotting time between conditions in the presence vs. absence of calcium) compared to 
964 phospholipid dependence (right side) (the shift in clotting time between conditions in the 
965 presence vs. absence of phospholipid) of venoms, where warmer colours represent less 
966 dependence on the cofactor. Calcium dependence showed an extremely strong correlation 
967 with phospholipid dependence (PGLS df = 1, t = 7.7003, p = 3.592x 10 -08) and was a good 
968 predictor of the latter parameter. Error bars at the nodes indicate 95% confidence intervals 
969 for the estimate at each node. Note: due to the high dynamicity of venom evolution, the 
970 ranges quickly become broad as one moves down the tree. Lineages in grey are non-
27
971 coagulotoxic. ND = Not detectable due to non-procoagulant venom. Negative values 
972 indicate that clotting times were quicker in the absence of phospholipid. 
973
974 Figure 5. Ancestral state reconstruction of antivenom efficacy as determined by (AUC for 
975 runs with venom preincubated with antivenom)/(AUC with venom only), where warmer 
976 colours represent greater neutralisation of venoms by the antivenom. The selectivity of 
977 Taipan ICP antivenom for Oxyuranus venoms compared to Pseudonaja venoms was highly 
978 significant (PGLS df = 1, t = 4.9364, p = 3.974 x 10-5). Error bars at the nodes indicate 95% 
979 confidence intervals for the estimate at each node. Note: due to the high dynamicity of 
980 venom evolution, the ranges quickly become broad as one moves down the tree. Lineages 
981 in grey are non-coagulotoxic. ND = Not detectable due to non-procoagulant venom.
982
983 Figure 6. Ancestral state reconstruction of clotting times (s) (left side) compared to 
984 substrate cleavage (right side) of venoms, where warmer colours represent faster clotting 
985 times or higher substrate cleavage activity (FXa activity). Factor Xa activity was found to 
986 have only a moderately non-significant correlation as a predictor of clotting time (PGLS df 
987 = 1, t = -1.9682, p = 0.0598) (note: the negative t-value is due to the two variables being 
988 inversely related). Error bars at the nodes indicate 95% confidence intervals for the estimate 
989 at each node. Lineages in grey are non-coagulotoxic. ND = Not detectable due to non-
990 procoagulant venom. Note: due to the high dynamicity of venom evolution, the ranges 
991 quickly become broad as one moves down the tree. 
992
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994 Table 1. Mean clotting times, antivenom efficacy, and calcium and phospholipid dependence (presented by mean ± SD), 
995 at 20 μg/mL venom concentration of Oxyuranus and Pseudonaja venoms 
Species (locality), sex Clotting 
time (s)
AV efficacy* Calcium 
dependence**
Phospholipid 
dependence **
O. microlepidotus (Boulia, QLD), m 9.5 ± 0.46 1.21 ± 0.01 3.61 ± 0.11 0.38 ± 0.03
O. microlepidotus (Coober Pedy, SA), unk. 9.47 ± 0.15 1.84 ± 0.05 3.8 ± 0.54 0.52 ± 0.22
O. scutellatus (Port Moresby, PNG), unk. 8.47 ± 0.06 1.82 ± 0.07 3.56 ± 0.39 0.61 ± 0.06
O. scutellatus (Saibai Island, PNG), unk. 7.6 ± 0.1 1.87 ± 0.04 1.53 ± 0.26 -0.03 ± 0.01
O. scutellatus (Cooktown, QLD), f 10.2 ± 0.85 2.22 ± 0.04 2.79 ± 0.05 0.33 ± 0.23
O. scutellatus (Gladstone, QLD), m 8.33 ± 0.59 1.84 ± 0.01 2.25 ± 0.21 0 ± 0.02
O. scutellatus (Julatten, QLD), m 8.2 ± 0.4 2.28 ± 0.24 2.25 ± 0.17 0.08 ± 0.02
O. temporalis (Ilkurka, WA), f 421.0 ± 4.7 ––– ––– –––
O. temporalis (Ilkurka, WA 2), m 626.5 ± 57.8 ––– ––– –––
P. affinis (Esperance, WA), m 6.4 ± 0.27 0.93 ± 0.02 2.17 ± 0.39 0.28 ± 0.12
P. affinis (Perth, WA), unk. 6.93 ± 0.12 0.85 ± 0.01 2.62 ± 0.11 0.45 ± 0.06
P. aspidorhyncha (Dubbo, NSW), m 6.7 ± 0.17 0.89 ± 0.09 1.13 ± 0.08 0.29 ± 0.04
P. aspidorhyncha (St. George, QLD), unk. 7.57 ± 0.15 0.83 ± 0.01 3.03 ± 0.11 0.57 ± 0.04
P. guttata (Longreach, QLD), pooled 6.0 ± 0.29 0.42 ± 0.01 0.45 ± 0.07 -0.17 ± 0.04
P. inframacula (Eyre Peninsula, SA), unk. 8.4 ± 0.1 0.86 ± 0.01 2.76 ± 0.2 0.61 ± 0.08
P. inframacula (York Peninsula, SA), unk. 7.63 ± 0.31 0.88 ± 0.14 2.53 ± 0.24 0.28 ± 0.03
P. ingrami (NT), unk. 5.53 ± 0.47 0.58 ± 0.02 1.88 ± 0.53 -0.16 ± 0.05
P. ingrami (QLD), unk. 5.53 ± 0.15 0.81 ± 0.03 1.65 ± 0.03 0.06 ± 0.01
P. mengdeni (Alice Springs, NT), m 5.53 ± 0.12 0.39 ± 0.12 0.96 ± 0.06 -0.01 ± 0.01
P. mengdeni (Kununurra, WA), m 5.7 ± 0.1 0.92 ± 0.00 1.04 ± 0.02 -0.09 ± 0.02
P. mengdeni (Shay Gap, WA), unk. 6.1 ± 0.1 0.09 ± 0.02 0.88 ± 0.09 -0.33 ± 0.01
P. modesta (Sandstone, WA), unk. 337.0 ± 4.4 ––– ––– –––
P. nuchalis (Darwin, NT), m 6.23 ± 0.32 0.60 ± 0.00 0.24 ± 0.01 -0.26 ± 0.06
P. nuchalis (Darwin, NT 2), m 6.07 ± 0.15 0.63 ± 0.03 0.38 ± 0.03 -0.21 ± 0.04
P. textilis (Barossa, SA), unk. 5.4 ± 0.17 0.47 ± 0.00 0.7 ± 0.03 -0.05 ± 0.01
P. textilis (Gold Coast, QLD), unk. 5.57 ± 0.4 0.55 ± 0.00 0.35 ± 0.16 -0.27 ± 0.04
P. textilis (Mackay, QLD), unk. 5.6 ± 0.1 0.46 ± 0.01 0.56 ± 0.25 -0.15 ± 0.01
P. textilis (Redbank, QLD), unk. 5.4 ± 0.2 0.47 ± 0.01 0.49 ± 0.05 -0.2 ± 0.01
997 * Antivenom efficacy, as described in Materials and Methods section 2.6, was calculated using the relationship (AUC for 
998 venom + antivenom ÷ AUC for venom alone), then subtracted by 1 (so that no shift in AUC values (a value of 1 divided by 1) 
999 would have a value of 0 instead of 1). ** Calcium and phospholipid dependence are indicated as the x-fold shift in clotting time 
1000 between conditions in the presence vs. absence of calcium or phospholipid, as described in Materials and Methods section 2.5. 
1001 Abbreviations: O.= Oxyuranus; P.= Pseudonaja; unk. = unknown; f = female; m = male; NT = Northern Territory; QLD = 
1002 Queensland; SA = South Australia; NSW = New South Wales; WA = Western Australia; ––– = not assessed because of non-
1003 procoagulant venom.
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Supplementary figures
Figure S1. Ancestral state reconstruction of calcium dependency at 5ug/mL (left side) compared to 20ug/mL 
(right side) venom concentration. The shift in clotting time between conditions in the presence vs. absence of 
calcium is represented by warmer colours for lower dependence on calcium. Error bars at the nodes indicate 
95% confidence intervals for the estimate at each node. Note: due to the high dynamicity of venom evolution, 
the ranges quickly become broad as one moves down the tree. Lineages in black are non-coagulotoxic. ND=Not 
Detectable, with clotting times >999 sec. Lineages in grey were not assessed due to lack of venom. Numbers at 
tips are calcium dependency means at the respective venom concentrations. 
Figure S2. Ancestral state reconstruction of phospholipid dependence at 5ug/mL (left side) compared to 
20ug/mL (right side) venom concentration. The shift in clotting time between conditions in the presence vs. 
absence of phospholipid is represented by warmer colours for lower dependence on phospholipid. Error bars at 
the nodes indicate 95% confidence intervals for the estimate at each node. Note: due to the high dynamicity of 
venom evolution, the ranges quickly become broad as one moves down the tree. Lineages in black are non-
coagulotoxic. ND=Not Detectable, with clotting times >999 sec. Lineages in grey were not assessed due to lack 
of venom. Numbers at tips are phospholipid dependency means at the respective venom concentrations. 
Negative values indicate that clotting times were quicker in the absence of phospholipid. 
